Stephen D Weigand

List of Publications by Year
in descending order

67 papers	5,688 citations	147801 31 h-index	102487 66 g-index
67 all docs	67 docs citations	67 times ranked	7034 citing authors

#	Article	IF	Citations
1	Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 441-452.	3.0	8
2	Detection of Alzheimer's disease amyloid beta 1â€42, pâ€tau, and tâ€tau assays. Alzheimer's and Dementia, 2022, 18, 635-644.	0.8	28
3	Leftâ€"Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T 1 Weighted MRI Images. Journal of Magnetic Resonance Imaging, 2022, , .	3.4	3
4	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. NeuroImage: Clinical, 2022, 34, 102999.	2.7	11
5	Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years. Neurology, 2022, 98, .	1.1	10
6	Response to â€œOn the reproducibility of quantitative susceptibility mapping and its potential as a clinical biomarker: A comment on Cogswell etÂal. 2021â€• NeuroImage, 2022, 251, 118992.	4.2	0
7	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. Movement Disorders, 2022, 37, 702-712.	3.9	14
8	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Communications, 2022, 4, .	3.3	5
9	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. Acta Neuropathologica, 2022, 144, 159-160.	7.7	14
10	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	4.2	63
11	Iron Heterogeneity in Early Active Multiple Sclerosis Lesions. Annals of Neurology, 2021, 89, 498-510.	5.3	22
12	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. Journal of Neurology, 2021, 268, 3409-3420.	3.6	12
13	<scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156.	5.3	31
14	CSF dynamics as a predictor of cognitive progression. NeuroImage, 2021, 232, 117899.	4.2	3
15	<scp>Magnetic Resonance Imaging</scp> Correlates of Multiple Sclerosis Immunopathological Patterns. Annals of Neurology, 2021, 90, 440-454.	5.3	12
16	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2669-2675.	3.9	4
17	Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes. Neurology, 2021, 97, e1906-e1913.	1.1	18
18	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	4.2	24

#	ARTICLE	IF	CITATIONS
19	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	3.1	11
20	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36.	3.1	7
21	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	7.6	74
22	Longitudinal Amyloid-β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	2.6	7
23	Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	5.3	32
24	CSF biomarkers in Olmsted County. Neurology, 2020, 95, e256-e267.	1.1	14
25	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage: Clinical, 2020, 25, 102152.	2.7	46
26	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer's Association Research Framework. JAMA Neurology, 2019, 76, 1174.	9.0	182
27	The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	7.6	129
28	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiology of Aging, 2019, 77, 26-36.	3.1	51
29	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	7.4	223
30	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.1	62
31	Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa. Alzheimer's and Dementia, 2019, 15, 799-806.	0.8	14
32	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathologica, 2019, 137, 227-238.	7.7	65
33	Predicting Progression to Mild Cognitive Impairment. Annals of Neurology, 2019, 85, 155-160.	5.3	32
34	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.1	55
35	[18F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	5.3	67
36	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain, 2018, 141, 271-287.	7.6	218

#	Article	IF	Citations
37	Dark Rims: Novel Sequence Enhances Diagnostic Specificity in Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 1052-1058.	2.4	14
38	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.8	80
39	Longitudinal tau PET in ageing and Alzheimer's disease. Brain, 2018, 141, 1517-1528.	7.6	309
40	Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathologica, 2017, 133, 597-612.	7.7	53
41	Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study. Lancet Neurology, The, 2017, 16, 435-444.	10.2	241
42	Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions. Acta Neuropathologica, 2017, 134, 45-64.	7.7	94
43	Brain tau deposition linked to systemic causes of death in normal elderly. Neurobiology of Aging, 2017, 50, 163-166.	3.1	2
44	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. Neurology, 2017, 89, 2271-2279.	1.1	30
45	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurology, The, 2017, 16, 917-924.	10.2	159
46	[18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	3.9	136
47	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. NeuroImage, 2017, 144, 113-127.	4.2	59
48	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.8	581
49	In vivo detection of connectivity between cortical and white matter lesions in early MS. Multiple Sclerosis Journal, 2017, 23, 973-981.	3.0	4
50	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. Journal of Alzheimer's Disease, 2016, 55, 1069-1082.	2.6	30
51	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clinical, 2016, 11, 802-812.	2.7	249
52	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.1	22
53	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	3.1	20
54	Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathologica, 2016, 131, 571-585.	7.7	244

#	Article	IF	Citations
55	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurology, The, 2016, 15, 56-64.	10.2	104
56	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. NeuroImage: Clinical, 2016, 11, 90-98.	2.7	10
57	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurology, 2016, 73, 85.	9.0	160
58	Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Annals of Neurology, 2015, 78, 710-721.	5.3	485
59	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2015, 45, 1109-1117.	2.6	19
60	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. Journal of Neurology, 2015, 262, 2064-2072.	3.6	10
61	Age, Sex, and <i>APOE</i> Îµ4 Effects on Memory, Brain Structure, and Î²-Amyloid Across the Adult Life Span. JAMA Neurology, 2015, 72, 511.	9.0	305
62	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain, 2015, 138, 3747-3759.	7.6	170
63	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	9.0	23
64	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.1	73
65	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimer's and Dementia, 2014, 10, 779-789.	0.8	26
66	Age-specific population frequencies of cerebral Î²-amyloidosis and neurodegeneration among people with normal cognitive function aged 50â€"89 years: a cross-sectional study. Lancet Neurology, The, 2014, 13, 997-1005.	10.2	297
67	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	3.1	108